Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
US11654157B2 · kind B2 · utility
0Cited by
6References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 9, 2018 |
| Grant date | May 23, 2023 |
| Priority date | — |
| Expiry date | Jan 9, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2121/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.